Search
Product Action
Conjugates
Low Endotoxin
Sample Size
Reviews
Brand
BET bromodomain inhibitor; orally bioavailable
| Alternate Names: | Birabresib |
| Chemical Name: | (6S)-4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide |
| Purity: | ≥98% (HPLC) |
Potent and selective BET bromodomain inhibitor; cell permeable
| Chemical Name: | (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester |
| Purity: | ≥98% (HPLC) |
BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes
| Chemical Name: | 7-(3,5-Dimethyl-4-isoxazolyl)-1,3-dihydroxy-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]quinolin-2-one dihydrochloride |
| Purity: | ≥98% (HPLC) |
Potent and selective ATAD2 bromodomain inhibitor
| Chemical Name: | (1R,2R,5S)-11-(8-((1-(2-Fluoro-2-methylpropyl)piperidin-4-yl)amino)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine-6-carbonyl)-2-isopropyl-2,3,5,6-tetrahydro-1,5-epiminobenzo[d]azocin-4(1H)-one |
| Purity: | ≥98% (HPLC) |
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
| Chemical Name: | N-Methyl-N-[3-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]acetamide |
| Purity: | ≥98% (HPLC) |
Potent and high affinity BET bromodomain inhibitor; anti-inflammatory; orally bioavailable.
| Alternate Names: | GSK525762A,Molibresib |
| Chemical Name: | (4S)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide |
| Purity: | ≥98% (HPLC) |
Potent and selective SMARCA2/4 and PB1(bromo 5)-selective SWI/SNF bromodomain inhibitor
| Chemical Name: | 1,1-Dimethylethyl 4-[3-amino-6-(2-hydroxyphenyl)-4-pyridazinyl]-1-piperazinecarboxylate bromodomains |
| Purity: | ≥98% (HPLC) |
BET bromodomain inhibitor; arrests cell cycle at G1 phase
| Alternate Names: | TEN 010 |
| Chemical Name: | (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide |
| Purity: | ≥98% (HPLC) |
Broad spectrum bromodomain inhibitor
| Chemical Name: | N-[(6-3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate |
| Purity: | ≥98% (HPLC) |
Potent and selective BRPF bromodomain inhibitor
| Chemical Name: | 4-Cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzene-1-sulfonamide |
| Purity: | ≥98% (HPLC) |
BET bromodomain inhibitor
| Chemical Name: | 2-Methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide |
| Purity: | ≥98% (HPLC) |
High affinity and selective PCAF bromodomain inhibitor
| Chemical Name: | (1S, 2S)-N1,N1-Dimethyl-N2-(3-methyl-1,2,4-triazolo[3,4-a]phthalazin-6-yl)-1-phenylpropane-1,2-diamine dihydrochloride |
| Purity: | ≥98% (HPLC) |
Negative Control for MZ 1 (Cat. No. 6154)
| Chemical Name: | (2S,4S)-1-((S)-2-(tert-butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)- 4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
| Purity: | ≥98% (HPLC) |
(+)-JQ1 based Degrader (PROTAC®) that preferentially degrades BRD4
| Chemical Name: | (2S,4R)-1-((S)-2-(tert-butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)- 4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
| Purity: | ≥98% (HPLC) |
Potent and selective BRD4(1) inhibitor
| Chemical Name: | (E)-4-[2-(2-Amino-4-hydroxy-5-methylphenyl)diazenyl]-N-2-pyridinylbenzenesulfonamide |
| Purity: | ≥98% (HPLC) |
Potent and selective (+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo
| Chemical Name: | (6S)-4-(4-Chlorophenyl)-N-[8-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]octyl]-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide |
| Purity: | ≥98% (HPLC) |
CBP inhibitor; cell permeable
| Chemical Name: | 5-[(1E)-2-(2-Amino-4-hydroxy-5-methylphenyl)diazenyl]-2,4-dimethylbenzenesulfonic acid sodium salt |
| Purity: | ≥99% (HPLC) |
Potent SMARCA2/4 inhibitor
| Chemical Name: | N-[(1S)-1-(Methoxymethyl)-2-[[4-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-thiazolyl]amino]-2-oxoethyl]-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide |
| Purity: | ≥95% (HPLC) |
(+)-JQ1 based PROTAC® with selectivity for BRD4
| Chemical Name: | (2S,4R)-1-(2R)-2-Acetamido-3-[[6-[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetamido]hexyl]thio]-3-methylbutanoyl]-4-hydroxy-N-[4-(4-methylthiazol-5-yl)benzyl)pyrrolidinine-2-carboxamide |
| Purity: | ≥98% (HPLC) |
(+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo
| Chemical Name: | (6S)-4-(4-Chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide |
| Purity: | ≥98% (HPLC) |
BET bromodomain Degrader (PROTAC®); also potent Hedgehog pathway inhibitor
| Chemical Name: | 2-Methoxyethyl 4-(3-((1-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-7-(2-methoxyphenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate |
| Purity: | ≥98% (HPLC) |
Selective BAZ2 inhibitor
| Chemical Name: | 4-[4-(1-Methyl-1H-pyrazole-4-yl)-1-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-1H-imidazol-5-yl]benzonitrile |
| Purity: | ≥98% (HPLC) |
Selective MLLT1/3 inhibitor
| Chemical Name: | N-[2-[[(2S)-2-Methyl-1-pyrrolidinyl]methyl]-1H-benzimidazol-6-yl]-6-isoquinolinecarboxamide |
| Purity: | ≥98% (HPLC) |
Selective BRPF1B and BRPF2 inhibitor
| Chemical Name: | 4-Bromo-N-(2,3-dihydro-6-methoxy-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-methylbenzenesulfonamide |
| Purity: | ≥98% (HPLC) |
